Welcome to our dedicated page for SELLAS Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences Group, Inc. filings document a Nasdaq-listed clinical biopharmaceutical company developing cancer therapeutics, including GPS and SLS009 programs in acute myeloid leukemia. Form 8-K reports cover operating results, financial condition, corporate updates, clinical program disclosures, and material agreements.
The filing record also includes capital-structure disclosures for common stock and warrants, warrant inducement agreements and exercise proceeds, share-count updates, and facility-related agreements. Proxy materials document annual meeting proposals, stockholder voting procedures, and governance matters.
SELLAS Life Sciences Group, Inc. reported second quarter 2026 results and a corporate update. The late-stage oncology company is advancing its lead programs GPS and SLS009 in acute myeloid leukemia (AML) and exploring SLS009 in solid tumors such as pancreatic ductal adenocarcinoma.
For the quarter ended June 30, 2026, SELLAS recorded a net loss of $9.6 million, or $0.05 per share, compared with a net loss of $6.6 million, or $0.07 per share, a year earlier. Operating expenses rose to $10.6 million from $6.9 million, driven mainly by higher research and development spending to support the Phase 3 REGAL trial of GPS and potential BLA preparation, as well as increased general and administrative costs.
As of June 30, 2026, cash and cash equivalents totaled $138.3 million. The Phase 3 REGAL trial in AML is approaching the pre-specified 80th event that will trigger final efficacy analysis. The Phase 2 SLS009 trial in newly diagnosed AML has enrolled 28 of a planned 80 patients, with topline data expected in the fourth quarter of 2026. Preclinical data suggest SLS009 activity in pancreatic cancer models resistant to RAS inhibitors, with clinical development preparations underway.
SELLAS Life Sciences Group, Inc. reported results for the quarter ended June 30, 2026, showing a continued development-stage profile with a stronger balance sheet. Cash and cash equivalents were $138.3 million, up from $71.8 million at December 31, 2025, largely driven by $82.9 million of warrant exercise proceeds. Total assets were $145.4 million against modest total liabilities of $7.7 million, resulting in stockholders’ equity of $137.7 million.
For the three months ended June 30, 2026, SELLAS incurred a net loss of $9.6 million (vs. $6.6 million a year earlier), and a six‑month net loss of $18.0 million (vs. $12.4 million). Research and development expenses rose to $6.3 million for the quarter and $11.4 million year‑to‑date, reflecting increased GPS manufacturing, clinical work on the REGAL AML study, and SLS009 trials. General and administrative expenses increased to $4.4 million for the quarter and $8.5 million for six months, including a $1.0 million arbitration-related charge.
The company states that, based on current plans, its cash is expected to fund operations for at least twelve months from issuance of the financial statements, while it continues late‑stage development of GPS and advances SLS009 into randomized Phase 2 studies in AML. Management also highlights substantial remaining potential milestones under its 3D Medicines and GenFleet licensing arrangements, although no new licensing revenue was recognized in the period.
State Street Corporation and certain investment adviser subsidiaries reported passive ownership of common stock of SELLAS Life Sciences Group Inc on a Schedule 13G. As of 06/30/2026, they beneficially owned 12,996,558 shares of common stock, representing 7% of the outstanding class. The group held 12,677,559 shares with shared voting power and 12,996,558 shares with shared dispositive power, with no sole voting or dispositive authority reported. Subsidiaries involved include SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 9,666,278 securities of SELLAS Life Sciences Group Inc, representing 5.19% of the common stock class identified by CUSIP 81642T209 as of June 30, 2026. Vanguard reports sole voting power over 1,400,173 securities and sole dispositive power over all 9,666,278 securities, with no shared voting or dispositive power. The position is held by Vanguard Capital Management LLC together with specified affiliates and business divisions, and consists of warrants, even though the CUSIP corresponds to the issuer’s ordinary shares. Vanguard notes that various Vanguard funds and managed accounts have the right to receive dividends or sale proceeds on these securities, but no other single person has an interest in more than 5% of the class.
SELLAS Life Sciences Group, Inc. estimates unaudited cash and cash equivalents of $138.3 million as of June 30, 2026, subject to completion of financial closing procedures and management review.
The company reports that on July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre dismissed its claims against 3D Medicines, Inc. and allocated approximately $1.0 million of 3D Medicines’ legal fees and costs to be paid by SELLAS. Under an existing exclusive license for galinpepimut-S in the Greater China territory, 3D Medicines announced it will continue development and commercialization, with $191.5 million in potential future milestone payments remaining as of March 31, 2026, including $13.0 million that had been in dispute.
SELLAS Life Sciences Group, Inc. updated executive compensation arrangements related to severance and change of control protection. The company amended CEO Dr. Angelos Stergiou’s employment agreement so that certain change of control severance payments will be made in a lump sum, with all other terms unchanged.
SELLAS also entered into amended and restated severance and change of control letter agreements with CFO John Burns and Chief Development Officer Dr. Dragan Cicic. Outside a change of control, each may receive nine months of base salary, a pro rata target bonus, and up to nine months of COBRA reimbursement if terminated without Cause or resigning for Good Reason. If such a termination occurs within the defined change of control period, each may receive lump sum payments equal to 15 months of base salary, a full target bonus, up to 18 months of COBRA reimbursement, and full vesting of unvested equity awards, subject to signing a separation and general release.
SELLAS Life Sciences Group, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. A total of 115,511,771 shares, representing approximately 62.59% of outstanding common stock, were present in person or by proxy, establishing a valid quorum.
Stockholders re-elected Class I directors Robert Van Nostrand and Jane Wasman to serve until the 2029 Annual Meeting, ratified Baker Tilly US, LLP as independent auditor for the year ending December 31, 2026, and approved an amendment to the 2023 Equity Incentive Plan to add 20,000,000 shares. They also approved the advisory vote on executive compensation and an adjournment proposal to solicit additional proxies if needed.
Stergiou Angelos M. reported acquisition or exercise transactions in this Form 4 filing.
SELLAS Life Sciences Group reported that President and CEO Angelos M. Stergiou received a grant of 1,065,000 restricted stock units on June 16, 2026. These RSUs vest 25% on December 1, 2026 and 25% on each December 1 thereafter, subject to continued service, bringing his direct holdings to 1,759,183 shares.
SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count. The company had $107.1 million in cash and cash equivalents as of March 31, 2026. In April and May 2026, it received about $28.7 million from the exercise of common stock warrants, adding to its liquidity.
As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding, giving investors a clearer picture of the current capital structure.
SELLAS Life Sciences Group, Inc. reported a first quarter 2026 net loss of $8.4 million, or $0.05 per share, wider than the $5.8 million loss, or $0.07 per share, a year earlier. Higher research and development expenses of $5.1 million and general and administrative expenses of $4.1 million drove the increase as the company invested in clinical programs and regulatory preparation.
Cash and cash equivalents rose to $107.1 million as of March 31, 2026, with an additional $7.5 million received in the second quarter from warrant exercises. SELLAS highlighted progress in its pivotal Phase 3 REGAL trial of GPS in acute myeloid leukemia, with 78 of 80 required events reached as of May 11, 2026, and ongoing dosing in a Phase 2 trial of SLS009 in newly diagnosed AML. The company also put in place an at-the-market equity offering program allowing up to $150 million in future capital raises.